

Cumulated Subject Index Vol. 5/6, 1973

A

- Acne vulgaris
 - ethyl lactate treatment 6: 66
 - sulphur therapy 5: 337
- ACTH
 - nasal polypi 6: 289
- β -Adrenergic receptor blocking drugs
 - drug interactions 5: 190
 - levodopa interactions 6: 375
- Alcohol
 - drug interactions 5: 190
- Alcoholism
 - disulfiram implantation 6: 450
- Alginate
 - gastro-oesophageal reflux prevention 5: 450
- Alopecia
 - contraceptives, oral 6: 278
- Amantadine
 - levodopa interactions 6: 373
- Amiloride
 - heart failure, refractory 5: 325, 328
 - potassium repletion
 - clinical use 6: 226-229
 - severe cardiac disease 6: 277-278
- Amines
 - pain, role in 5: 111
- Aminocaproic acid
 - inhibition action streptokinase 5: 375, 408
- Amiripityline
 - response to 5: 234
 - + triiodothyronine 5: 236
- Amoebiasis
 - cause 6: 407
 - treatment 6: 412
- Amphetamines
 - levodopa interactions 6: 374
- Ampicillin
 - compared with
 - pivampicillin 6: 95-98, 100
 - esters of 6: 94
 - gonorrhoea 5: 151
 - otitis media in neonates 5: 344
 - urinary infection
 - compared with
 - cephalexin 5: 472
 - co-trimoxazole 5: 472

Anaemia

- children 6: 252-253
- iron deficiency 6: 245-248
- megaloblastic 6: 249-251
- pregnancy 6: 251
- renal failure, chronic 6: 249
- treatment 6: 224-254
- Anaesthesia
 - morphine 6: 305-309
 - nitrous oxide-oxygen
 - pentazocine supplementation 5: 36-37
 - pentazocine supplementation 5: 34-37
 - pregnancy 5: 335
- Anaesthesia, general
 - antihypertensive therapy 6: 357
 - myocardial infarction after 5: 333
- Anaesthetics
 - drugs, the kidney and 5: 246-252
 - renal excretion 5: 252
 - renal failure 5: 248-249
- Anaesthetics, general
 - drug interactions 5: 191
- Analgesic activity
 - morphine 5: 51-52
 - pentazocine 5: 44-45, 51-52
 - site of action 5: 45
- Analgesics
 - drug interactions 5: 192
 - drug trial design 5: 13-14
 - intramuscular efficacy 5: 24, 28
 - morphine *qv*
 - pentazocine *qv*
 - pethidine *qv*
- Analgesics, strong 5: 108-143
 - analgesic efficacy 5: 117
 - childbirth 5: 134, 137
 - children 5: 137
 - clinical use 5: 133-137
 - acute pain 5: 133, 134-137
 - chronic pain 5: 133-134
 - drug interactions 5: 128-130
 - elderly 5: 137
 - myocardial infarction 5: 135, 137
 - pharmacokinetics 5: 126-128
 - absorption 5: 126
 - distribution 5: 126

- excretion 5: 127
- biotransformation 5: 127
- pharmacological effects 5: 116-121
- postoperative pain 5: 136, 137
- trauma 5: 136
- Ancrod**
 - thrombosis, deep vein 5: 394
- Angina pectoris**
 - streptokinase 5: 427
- Anileridine**
 - analgesic activity 5: 122
 - duration intramuscular dose 5: 117
 - oral efficacy 5: 117
- Antacids**
 - gastro-oesophageal reflux 5: 451
- Antianxiety drugs**
 - principles of use 6: 398
- Antiarrhythmic agents**
 - classes 5: 257-258, 272-274
 - clinical application 5: 274-289
 - dosage 5: 294
 - electrophysiological action 5: 269-272
 - haemodynamic effects 5: 311-314
 - pharmacokinetics 5: 274-289
 - modes of action 5: 257-258, 274-289
 - toxicity 5: 274-289
- Antibacterial agents**
 - drug interactions 5: 193-195
 - interstitial tissue fluid 6: 276-277
 - pivampicillin 6: 94-103
- Antibiotics**
 - diarrhoea, travellers' 6: 411
- Anticholinergic drugs**
 - levodopa interactions 6: 372
- Anticoagulants**
 - cerebral ischaemic attacks, transient 6: 52-54
 - drug interactions 5: 195-196
 - myocardial infarction, after 6: 291
 - streptokinase post infusion 5: 437
 - streptokinase therapy 5: 380
- Anticonvulsant activity**
 - pentazocine 5: 48
- Anticonvulsants**
 - congenital abnormalities 5: 467-468
 - drug interactions 5: 196-197
- Antidepressants**
 - drug interactions 5: 198-199
- Antidepressants, tricyclic**
 - interaction with
 - antihypertensive drugs 6: 356
 - levodopa interactions 6: 374
 - principles of use 6: 395
 - potentiation of by thyroid 5: 235, 236
- Antifibrinolytic agents**
 - inhibition action streptokinase 5: 375-376, 408
- Antifungal agents**
 - drug interactions 5: 199
- Antihistamines**
 - drug interactions 5: 200
 - antihypertensive drugs 6: 344
 - patch test results 5: 349
- Antihypertensive drugs**
 - anaesthesia, general 6: 357
 - β -adrenergic receptor blockers 5: 470
 - clonidine 5: 469
 - combined use 6: 344-345
 - drug interactions 5: 200-201, 6: 354-358
 - elderly 6: 360-361
 - hypertensive crisis 6: 359-360
 - mode of action 6: 339-344
 - pregnancy 6: 358
 - principles of therapy 6: 350-352
 - selection of 6: 345, 349
 - side-effects 6: 344, 346-348
 - site of action 6: 342-343
- Anti-inflammatory drugs**
 - mechanism of action 6: 104-117
 - bradykinin 6: 107
 - histamine 6: 106
 - lysosomes 6: 110
 - prostaglandin synthesis 6: 112-114
 - serotonin 6: 106
 - protein binding 6: 113, 115
- Antimalarial drugs**
 - drug interactions 5: 201
- Antimicrobial agents**
 - drug interactions 5: 171, 184, 193-195, 199, 202-203
- Antineoplastic drugs**
 - drug interactions 5: 201-202
- Antiparkinsonian drugs**
 - drug interactions 5: 202
 - levodopa interactions 6: 364-388
- Antituberculosis drugs**
 - drug interactions 5: 202-203
- Antitussive activity**
 - pentazocine 5: 64
- Anxiety**
 - diagnosis 6: 389-399
 - treatment 6: 389-399
- Aphthous ulceration**
 - see ulceration, aphthous
- Apomorphine**
 - levodopa interactions 6: 374
- Aprotinin**
 - inhibition action streptokinase 5: 375, 408
- Arterial occlusions, non-recent**
 - streptokinase 5: 418-422
- Arterial occlusions, thromboembolic**
 - streptokinase 5: 398-406
- Arteritis, giant cell**
 - management 5: 215
- Arthritis**
 - gonococcal: management 6: 452
 - rubella vaccine 6: 433
- Aspirin**
 - anti-inflammatory action 6: 104-116
 - community consumption 6: 144
 - prostaglandin synthesis 6: 113
- Asthma**
 - assessment 6: 119
 - bronchodilators 6: 121-123
 - corticosteroids 6: 81-83, 123-124
 - metabolic clearance rate 6: 82
 - therapeutic use 6: 81-83
 - elderly 6: 151

- sodium cromoglycate 6: 124
- sodium cromoglycate long-term 6: 70-72
- treatment 5: 118-126
- severe 6: 81, 125, 152
- Atrial**
 - fibrillation
 - digoxin dosage 5: 238, 6: 431
 - treatment 5: 297
 - flutter
 - treatment 5: 296
 - premature systoles
 - treatment 5: 295
 - tachycardia 5: 296
- Azathioprine**
 - lupus erythematosus, systemic 6: 293
 - pemphigus 6: 288
- B**
- Barbiturates**
 - drug interactions 6: 150
- BCC**
 - Vaccination 6: 69
- Beclomethasone dipropionate**
 - asthma 6: 82, 84-93, 123
 - pharmacology 6: 86
 - rationale for use 6: 85
 - therapeutic efficacy 6: 86-90
- Benzathine penicillin**
 - syphilis 5: 152
- Benzocaine**
 - dermatitis 5: 332
- Benzylpenicillin**
 - gonorrhoea 5: 150
- Betamethasone 17-valerate**
 - eczema, atopic 6: 439
- Biliary tract infections**
 - cephalexin 6: 57
- Bioavailability**
 - digoxin 6: 209
- Blood coagulation**
 - mechanism 5: 365-367
- Blood pressure**
 - pentazocine 5: 57-59
- Blood viscosity**
 - streptokinase 5: 376-377
- Blood, whole**
 - rationale for use 6: 127-136
- Bone disease, metabolic**
 - elderly: treatment 6: 451
- Bowel syndrome, irritable**
 - management 6: 237-243
- Bradykinin**
 - inflammation: role in 6: 107
- Bran, unprocessed**
 - diverticular disease of colon 5: 237
- Breast lesions, benign**
 - contraceptives, oral 6: 314
- Bretylium**
 - cardiac arrhythmias
 - clinical application 5: 287, 298, 300
 - dosage 5: 294
 - modes of action 5: 286-287
 - toxicity 5: 288
- Bromhexine**
 - sinusitis, maxillary 6: 448
- Bronchitis**
 - nitrazepam in 6: 149
- Bronchodilators**
 - asthma 6: 121-123
 - interaction with
 - antihypertensive drugs 6: 556
- Butyrophenones**
 - levodopa interactions 6: 375
- C**
- Calcitonin**
 - clinical use 6: 440
- Cancer**
 - immunotherapy 5: 346
- Cancer, gynaecological**
 - analgesics, relative effects of 5: 30
 - pentazocine 5: 30
- Candida endophthalmitis**
 - management 5: 348
- Cannabis**
 - see marihuana
- Carbenoxolone**
 - drug interactions 5: 203
 - hypertension 6: 353
- Cardiac arrhythmias**
 - digitalis toxicity 5: 303-311
 - drug treatment
 - digitalis toxicity 5: 308-311
 - supraventricular tachyarrhythmias 5: 295-297
 - ventricular tachyarrhythmias 5: 298-300
 - electric pacing 5: 302
 - electroconversion 5: 300-302
 - electrophysiology 5: 263-267, 269-272
 - pathophysiology 5: 267-269
 - treatment 5: 257-260
 - treatment 5: 295-311
- Cardiac electrophysiology**
 - cardiac arrhythmias 5: 263-267, 269-272
- Cardiac glycosides**
 - drug interactions 5: 203
- Cardiotoxicity**
 - diazoxide 6: 67
 - d-thyroxine 6: 37
- Cardiovascular effects**
 - pentazocine 5: 46, 57-62
- Caries**
 - fluorides 5: 345
- Catechol-O-methyl-transferase inhibitors**
 - levodopa interactions 6: 372
- Catecholamine metabolising enzymes**
 - levodopa 6: 368
- Catecholamines**
 - uptake processes 6: 427
- Central nervous system effects**
 - pentazocine 5: 46-48
- Cephalexin**
 - biliary tract infections 6: 57
 - urinary infection
 - compared with
 - ampicillin 5: 472
 - co-trimoxazole 5: 472

- Cephalosporins
gonorrhoea 5: 151
- Cerebral ischaemic attacks, transient
blood pressure 6: 50
clinical features 6: 48, 49–50
diagnosis, differential 6: 50–51
history, natural 6: 51
management
 drug treatment 6: 48
 surgery 6: 48
pathogenesis 6: 46–47
patho-physiological considerations 6: 48
treatment
 anticoagulants 6: 48, 52–54
 surgery 6: 48, 52–53
- Cerebral thromboembolism, acute
streptokinase 5: 423–424
- Childbirth
analgesics, strong 5: 134, 137
- Children
analgesics, strong 5: 137
- Chlordiazepoxide
‘lupus erythematosus-like’ syndrome 6: 150
- Chlorpheniramine
demographism 6: 438
- Chlorquinaldol
dermatitis 5: 332
- Cholera
cause 6: 409
treatment 6: 410
- Cholera vaccine
international travel 6: 445
- Cholesterol, plasma
heart disease, coronary 6: 14, 64
‘normal limits’ 6: 22
polyunsaturated ruminant fats 6: 65
- Cholestyramine
drug interactions 5: 204, 6: 35
hyperlipoproteinaemia
 clinical use 6: 33
 side-effects 6: 34
 hypolipidaemic action 6: 28
- Cholinergic drugs
levodopa interactions 6: 372
- Cholinesterase inhibitors
interactions with
 analgesics, strong 5: 129
- Chylomicrons
function 6: 16
metabolism 6: 17
screening test 6: 31
- Clindamycin
colitis 6: 433
colitis, pseudomembranous 6: 280
- Clioquinol
dermatitis 5: 332
- Clofibrate
blood coagulation 6: 32, 33
drug interactions 6: 33
fibrinolytic system 6: 32
heart disease, coronary 6: 42–43
hyperlipoproteinaemia
 clinical use 6: 31
 hypolipidaemic action 6: 27
 side-effects 6: 32
- Clonidine
compared with
 methyldopa 5: 340
 hypertension 5: 469
- Cluster headache
diagnosis 5: 217
treatment 5: 218
- Coagulation, disseminated intravascular
streptokinase 5: 425–426
- Codeine
analgesic efficacy 5: 117, 121
duration intramuscular dose 5: 117
oral efficacy 5: 117
- Colestipol
hyperlipoproteinaemia
 clinical use 6: 35
 side-effects 6: 35
 hypolipidaemic action 6: 29
- Colitis
antibiotic-induced 6: 280
clindamycin 6: 433
- Colon
constipation 5: 221
muscle activity 5: 221–222
disorders of 5: 222
 purgative abuse 5: 226
- Colon, diverticular disease
bran, unprocessed 5: 237
- Colonic disease
laxatives 6: 61
- Complement system
inflammation: role in 6: 108
- Conjunctivitis
treatment 6: 267–269
 allergic 6: 272
 chlamydia 6: 270–271
 gonococcal 6: 269–270
 vernal 6: 273
- Connective tissue disease
corticosteroid therapy 5: 342
- Constipation
clinical causes 5: 221
pathogenesis 5: 220–224
treatment 5: 224–226
- Contraceptives, oral
breast lesions benign 6: 314
drug interactions 5: 204
hair loss 6: 278
hypertension 6: 59, 353
norethisterone 6: 169–181
norgestrel 6: 169–181
progestagen-only 6: 169–181
- Corticosteroids
anti-inflammatory action 6: 104–116
asthma 6: 123–124
 metabolic clearance rate 6: 82
 therapeutic use 6: 81–83
connective tissue disease 5: 342
drug interactions 5: 204, 6: 150
eczema, atopic 6: 439
intradermal use: plasma cortisol 6: 438

- lumbar disc disease 6: 437
- patch test results 5: 348
- Corticosteroids, aerosol
 - asthma 6: 84-93
 - beclomethasone dipropionate 6: 84-93
- Corticosteroids, topical
 - adverse effects 6: 279
 - dermatitis, rosacea-like 5: 227
 - oral ulceration treatment 5: 458-461
- Co-trimoxazole
 - gonorrhoea
 - H. influenzae resistant 5: 473
 - renal function: deterioration 6: 430
 - urinary infection
 - compared with
 - ampicillin 5: 472
 - cephalexin 5: 472
- CPP breathing
 - intra-abdominal operations 6: 311
- Cromoglycate, sodium
 - asthma 6: 124
 - long-term use 6: 70-72
 - rhinitis, allergic 6: 447
- Cromolyn sodium
 - see cromoglycate sodium
- Cytarabine
 - aricella-zoster 6: 444
- Cytotoxic drugs
 - drug interactions 5: 204
- D
 - Dental decay
 - fluorides 5: 345
 - Dental destruction
 - drug-induced 5: 229
 - Depression
 - antihypertensive drugs 6: 356
 - diagnosis 6: 389-399
 - drug induced 6: 392
 - elderly 6: 396
 - treatment 6: 297, 389-399
 - typologies and drug response 5: 234
 - Dermatitis
 - topical medicament-induced 5: 332
 - Dermatitis, rosacea-like
 - corticosteroids, strong 5: 227
 - Dermographism
 - chlorpheniramine 6: 438
 - hydroxyzine 6: 438
 - Deslanoside
 - see lanatoside C
 - Dextromoramide
 - analgesic activity 5: 123
 - duration intramuscular dose 5: 117
 - neuroleptanalgesia
 - compared with
 - pentazocine 5: 38
 - oral efficacy 5: 117
 - pharmacological effects 5: 123
- Diabetes mellitus
 - haemochromatosis 6: 74
 - oral therapy
 - need for continuation 6: 73
- Diabetic coma
 - insulin dosage 6: 457
- Diacetylmorphine
 - see diamorphine
- Diamorphine
 - analgesic activity 5: 121
 - duration intramuscular dose 5: 117
 - oral efficacy 5: 117
 - pain, cardiac
 - compared with
 - pentazocine 5: 41-42
 - pharmacological effects 5: 121
- Diarrhoea, travellers'
 - causes 6: 406-412
 - management 6: 406-412
 - prevention 6: 412
- Diazepam
 - pre-eclampsia 5: 343
 - premedicant
 - compared with
 - pentazocine 5: 33
- Diazoxide
 - arrhythmia following 6: 67
- Diet
 - constipation 5: 224
- Digitalis
 - assay 6: 194-196
 - cardiac arrhythmias
 - clinical application 5: 295, 296, 297, 300
 - clinical pharmacology 6: 182-221
 - dosage 6: 194
 - drug interactions 5: 203, 6: 209-213
 - electroconversion 5: 301
 - heart failure 5: 321-324, 327
 - heart failure
 - dosage 5: 322, 326, 327
 - modes of action 5: 303-305
 - myocardial infarction 6: 155
 - pharmacodynamic actions 6: 185-188
 - pharmacokinetics 5: 305-306, 322
 - principles of use 5: 321-322, 6: 207-209
 - therapeutic use 6: 182-221
 - toxicity 6: 189-194
 - clinical features 5: 303, 323-324, 333; 6: 189-190
 - electrophysiological effects 5: 303-305
 - epidemiology 6: 189
 - factors affecting 5: 305-308, 323
 - prevention 6: 394-196
 - treatment 5: 308-311, 6: 191-194
- Digitalis leaf
 - pharmacokinetics 6: 207
- Digitoxin
 - pharmacokinetics 5: 305-306, 322; 6: 206-207
 - renal failure 6: 213-216
- Digoxin
 - assay 6: 194-196, 200, 275
 - dosage 6: 431
 - atrial fibrillation
 - dosage 5: 157, 6: 431
 - intoxication 5: 157
 - bioavailability 6: 209

- clinical pharmacology 6: 165-166
- dosage in atrial fibrillation 5: 238
- drug interactions 6: 209-213
- elderly 6: 218
- electrolyte disturbances 6: 219
- heart disease, pulmonary 6: 219
- myocardial concentration 5: 338, 339
- myocardial infarction 6: 219
- obesity 6: 219
- patient compliance 6: 275
- pharmacokinetics 5: 305-306, 322, 338-339;
 - 6: 196-202
 - absorption 6: 201-202
 - excretion 6: 202
 - serum turnover 6: 197-200
- plasma concentration 5: 338
- renal failure 6: 213-216
- therapeutic use 6: 165-166
- thyroid disease 6: 216-218
- Dihydrocodeine
 - analgesic activity 5: 122
 - duration intramuscular dose 5: 117
 - oral efficacy 5: 117
- Dihydrohydroxycodone
 - see oxycodone 5: 122
- Dihydrohydroxymorphine
 - see oxymorphone
- Dihydromorphine
 - analgesic activity 5: 121
 - duration intramuscular dose 5: 117
 - oral efficacy 5: 117
- Diphenylhydantoin
 - see phenytoin
- Diphosphonates
 - myositis ossificans progressiva 5: 342
- Dipipanone
 - analgesic activity 5: 123
 - duration intramuscular dose 5: 117
 - oral efficacy 5: 117
 - pharmacological effects 5: 123
- Disulfiram
 - alcoholism 6: 450
- Diuretics
 - drug interactions 5: 204-205
 - heart failure 5: 324-328
 - potassium-sparing
 - clinical use 6: 225-229
 - potassium, total body 6: 146
 - urinary casts 5: 230
- Diverticular disease of colon
 - bran unprocessed 5: 237
- Dopa decarboxylase inhibitors
 - levodopa 6: 369
- Dopamine β -hydroxylase inhibitors
 - levodopa 6: 370
- Doxycycline
 - gonorrhoea 5: 151
- Drug absorption
 - drug interactions 5: 172-174
- Drug abuse
 - mandrax 6: 167-168
 - marhuana qv
 - methaqualone 6: 167-168
 - pentazocine 5: 82-83
- Drug bioavailability
 - generic equivalence 5: 464-465
- Drug dependence
 - pentazocine 5: 78-79, 80-84
- Drug distribution
 - drug interactions 5: 174
- Drug excretion
 - drug interactions 5: 180-182
 - renal mechanisms 5: 250-252
- Drug interactions 5: 161-211
 - analgesics, strong 5: 128-130
 - antihypertensive drugs 6: 354-358
 - antimicrobial agents 5: 171, 184, 193-195, 199, 202-203
 - barbiturates 6: 150
 - corticosteroids 6: 150
 - check-list to 5: 187-211
 - cholestyramine 6: 35
 - clinical importance 5: 163-164
 - examples of 5: 166-171, 190-211
 - clofibrate 6: 33
 - determinants 5: 164-165, 187-189
 - digitalis 6: 209-213
 - drug absorption 5: 172-174
 - drug distribution 5: 174
 - drug excretion 5: 180-182
 - drug metabolism 5: 176-180
 - electrolyte balance 5: 182-184
 - gastric emptying 5: 173
 - gastro-intestinal pH 5: 172
 - immunosuppressive agents 6: 428
 - interpretation of data 5: 162-165, 187-189
 - levodopa 6: 364-388
 - mechanisms 5: 165-185
 - monoamine oxidase inhibitors 5: 171, 184, 198; 6: 353
 - pentazocine 5: 77-78
 - protein binding 5: 174
 - receptors 5: 175
 - streptokinase 5: 432
- Drug medication
 - community consumption 6: 143-144
- Drug metabolism
 - drug interactions 5: 176-180
 - pentazocine 5: 3-4, 67-69
- Drug reactions, adverse
 - antihypertensive drugs 6: 344-348
 - chlorthalidoxepoxide 6: 150
 - cholestyramine 6: 34
 - clindamycin 6: 433
 - clofibrate 6: 32
 - colestipol 6: 35
 - contraceptives, oral 6: 59
 - corticosteroids, topical 5: 227
 - corticosteroids, topical 6: 279
 - dental destruction 5: 229
 - dermatitis: topical medicaments 5: 332
 - diazoxide 6: 67
 - digitalis toxicity 5: 303, 323, 333
 - diuretics
 - urinary casts 5: 230
 - drug interactions 5: 161-211

- fluphenazine enanthate
 - extrapyramidal reactions 5: 232
- gentamicin ototoxicity 5: 227
- isoniazid 5: 465, 466
- ketamine mental effects 5: 241-242
- laxatives 6: 61
- methotrexate 6: 60, 150
- nicotinic acid 6: 30
- oestrogens 6: 37
- pentazocine 5: 72-77
- phenothiazine withdrawal 5: 232
- rifampicin 5: 466
- rifampicin, intermittent 5: 230
- streptokinase 5: 428-430, 432
- tetracyclines and teeth 6: 321-323, 432
- d-thyroxine 6: 37
- ulceration, oral 5: 456-457
- Drug receptors
 - drug interactions 5: 175
- Drug therapy: multiple
 - drug interactions 5: 161-211
- Drug trials
 - analgesics 5: 13-14, 130-132
 - myocardial infarction 5: 409-410
- Dysmorphogens
 - anticonvulsants and epilepsy 5: 467-468
- Dysmorphology
 - pentazocine 5: 50
- E
- Eclampsia
 - diazepam-hydrallazine 5: 343
- Eczema
 - causes 6: 400-405
 - management 6: 400-405
- Eczema, atopic
 - betamethasone 17-valerate 6: 439
 - urea-hydrocortisone 6: 439
- Elderly
 - analgesics, strong 5: 137
 - antihypertensive drugs 6: 360
 - asthma 6: 151
 - bone disease, metabolic: treatment 6: 451
 - depression 6: 396
 - digoxin 6: 218
- Electroencephalograph
 - pentazocine effect 5: 65
- Electrolyte balance
 - drug interactions 5: 182-184
 - heart failure 5: 328-330
- Embolism, pulmonary
 - see pulmonary embolism
- Endophthalmitis, candida
 - management 5: 348
- Enzyme induction
 - drug interactions 5: 176-179
- Epilepsy
 - congenital malformations 5: 467-468
- Erythrocyte aggregation
 - streptokinase 5: 376-377
- Erythromycin
 - urethritis, nonspecific
- Erythromycin estolate
 - syphilis 5: 152
- Ethacrynic acid
 - heart failure 5: 325-328
 - urinary casts 5: 230
- Ethanol
 - drug interactions 5: 190
- Extrapyramidal reactions
 - fluphenazine enanthate 5: 231
 - phenothiazine withdrawal 5: 232
- F
- Faecal acidorrhoea
 - constipation, relationship 5: 222-223
- Fatty acids, free
 - levodopa interactions 6: 381
- Fenclonine
 - levodopa interactions 6: 378
- Fenfluramine
 - interaction with
 - antihypertensive drugs 6: 357
- Fentanyl
 - analgesic activity 5: 122
 - pharmacological effects 5: 122
- Fibrinolysis
 - stimulation of by drugs 5: 353-354
- Fibrinolytic system
 - function 5: 367-368
 - mechanism 5: 367-369
- Fluorides
 - dental caries 5: 345
- Fluphenazine enanthate
 - extrapyramidal reactions and antiparkinsonian
 - drugs 5: 231
- Fortalgesic
 - see pentazocine
- Fortral
 - see pentazocine
- Framycetin
 - leukaemia: septicemia prophylaxis 6: 455
- Frusemide
 - heart failure 5: 324-328
 - urinary casts 5: 230
- G
- Gastric emptying rate
 - drug interactions 5: 173
 - levodopa absorption 6: 367
- Gastrin
 - gastro-oesophageal reflux 5: 447, 451
- Gastroenteritis
 - infancy 6: 284-285
- Gastro-intestinal function
 - pentazocine 5: 48, 62-63
- Gastro-oesophageal reflux
 - mechanism preventing 5: 446-448
 - prevention 5: 450
- Gavison
 - gastro-oesophageal reflux prevention 5: 450
- Generic equivalence
 - bioavailability 5: 464-465
- Gentamicin
 - newborn

- dosage 6: 55-57
- ototoxicity 5: 227
- Glue ear
 - management 6: 290
- Gold
 - rheumatoid arthritis 5: 244-245
 - serum levels 6: 147
- Gonadotropins
 - levodopa interactions 6: 380
- Gonococcus
 - penicillin sensitivity 5: 150
- Gonorrhoea
 - diagnosis 5: 145-147
 - incidence 5: 144
 - pivampicillin 6: 99
 - treatment 5: 149-153
 - penicillin 5: 150-151
 - penicillin + probenecid 5: 150-151
 - ampicillin 5: 151
 - cephalosporins 5: 151
 - tetracyclines 5: 151
 - spectinomycin 5: 151
 - thiamphenicol 5: 151
 - co-trimoxazole 5: 152
 - spiramycin 5: 152
- Gout
 - diagnosis 5: 476
- Gout drugs
 - drug interactions 5: 206
- Growth hormone
 - levodopa interactions 6: 381
- Guanethidine
 - levodopa interactions 6: 376
- H
- Hair loss
 - contraceptives, oral 6: 278
- Half-life, plasma
 - pentazocine 5: 2-3, 67
- Hallucinogenic states
 - ketamine 5: 241-242
- Halothane
 - cardiovascular haemodynamic effects 6: 62
 - gastro-oesophageal reflux prevention 5: 450
- Headache
 - diagnosis 5: 212-219
 - treatment 5: 212-219
- Headache, contraction-tension
 - management 5: 218
- Headache, post concussional
 - management 5: 215-216
- Heart
 - pentazocine effect on 5: 59-60
- Heart disease
 - digitalis toxicity 5: 305
- Heart disease, coronary
 - cholesterol-lowering diet 6: 64
 - clofibrate 6: 5-6, 42-43
 - fat diets, modified 6: 435
 - hypolipidaemic drugs 6: 42-43
- Heart disease, pulmonary
 - digoxin 6: 219
- Heart failure
 - congestive
 - treatment 5: 318-325
 - diagnosis 5: 320
 - electrolyte imbalance 5: 328-330
 - investigation 5: 320
 - maintenance treatment 5: 331
 - refractory
 - treatment 5: 326-330
 - treatment 5: 318-331
- Heartburn
 - treatment 5: 446-452
- Heparin
 - pulmonary embolism, acute
 - compared with streptokinase 5: 383-387
 - thrombosis, deep vein 5: 394-396
- Hepatotoxicity
 - isoniazid 5: 465, 466
 - methotrexate 6: 148
 - rifampicin 5: 466
- Heroin
 - see diamorphine
- Herpes, genital
 - diagnosis 5: 149
- Herpetic gingivo-stomatitis
 - diagnosis 5: 455-456
 - treatment 5: 459-460
- Herpetiform aphthous ulcers
 - diagnosis 5: 455
 - treatment 5: 459
- Hexachlorophane
 - antimicrobial activity 5: 97
 - neurotoxicity 5: 97
 - pharmacokinetics 5: 99
 - skin care neonates 5: 97-107
 - dermal absorption 5: 100
 - efficacy 5: 104-105
 - neurotoxicity 5: 103
 - recommendations for use 5: 105
 - therapeutic efficacy 5: 104-105
 - toxicity 5: 97
- Histamine
 - inflammation: role in 6: 106
- Hydrallazine
 - pre-eclampsia 5: 343
- Hydrocortisone
 - eczema, atopic
 - + urea 6: 439
- Hydromorphone
 - see dihydromorphanone
- Hydroxyquinolines
 - dermatitis 5: 332
- Hydroxytryptophan
 - levodopa interactions 6: 378
- Hydroxyurea
 - psoriasis 6: 286
- Hydroxyzine
 - dermographism 6: 438
- Hyperlipidaemia
 - compared with streptokinase 5: 383-387
 - relationship to 6: 13-15
 - investigation 6: 2-3, 7-11, 20-22
 - management 6: 1-6

- normality 6: 5, 9,
reference guide to 6: 7-11
treatment 6: 3-5, 7-11, 25-41
treatment
 benefits 6: 41-42
 vascular disease premature 6: 2, 38-39
- Hyperlipoproteinaemia**
clinical features 6: 38-39
definitions of 6: 19
diagnosis 6: 38-39
dietary treatment 6: 40, 41
drug treatment 6: 25-41
mechanisms of 6: 18
primary forms 6: 38-39
neurotoxicity 5: 97
secondary forms 6: 38-39
treatment 6: 38-39
treatment
 benefits 6: 41-42
types 6: 19, 20-21
type I
 clinical features 6: 38
 diagnosis 6: 20
 incidence 6: 20, 38
 lipoprotein pattern 6: 22
type II
 clinical features 6: 38
 diagnosis 6: 20
 incidence 6: 20, 38
 lipoprotein pattern 6: 23
 treatment 6: 38, 40, 41
type III
 clinical features 6: 39
 diagnosis 6: 20
 incidence 6: 20, 39
 lipoprotein pattern 6: 24
 treatment 6: 39, 40, 41
type IV
 clinical features 6: 39
 diagnosis 6: 20
 incidence 6: 20, 39
 lipoprotein pattern 6: 24
 treatment 6: 39, 40, 41
type V
 clinical features 6: 39
 diagnosis 6: 20
 incidence 6: 20, 39
 lipoprotein pattern 6: 25
 treatment 6: 39, 40, 41
- Hyperpyrexia, malignant**
recognition 5: 243
treatment 5: 243-244
- Hypertension**
drug-induced 6: 352-354
drug treatment 6: 333-363
elderly 6: 360
hypertensive crisis 6: 359
initiation of treatment 6: 338
oral contraceptives 6: 59
pathogenesis 6: 334-336
rationale for lowering 6: 336-338
- Hyperuricaemia**
physiological basis of treatment 5: 474
- Hyperuricaemia, asymptomatic**
treat or not 5: 475
- Hypno-sedatives**
drug interactions 5: 206
- Hypoglycaemic agents**
drug interactions 5: 207
- Hypolipidaemic drugs**
benefits 6: 41-42
clinical use 6: 26, 29-41
hyperlipoproteinaemia 6: 25-41
lipoprotein metabolism 6: 26-29
- Hypothyroidism**
digitalis toxicity 5: 305
- I**
- Imipramine**
+ triiodothyronine 5: 235
tryptophan, compared with 5: 235
- Immunosuppressive Agents**
drug interactions in anaesthesia 6: 428
treatment 6: 39, 40, 41
causes 6: 413-416
treatment 6: 413-416
- Indomethacin**
anti-inflammatory action 6: 104-116
prostaglandin synthesis 6: 113
- Inflammation**
mediators of 6: 105
- Insulin release**
levodopa interactions 6: 381
- Intestinal transit**
dietary fibre 6: 443
- Intracranial pressure**
pentazocine effect 5: 63-64
- Iodine, radio-**
thyrotoxicosis 6: 441
- Iron deficiency**
treatment 6: 245-248
- Iron haematinics**
drug interactions 5: 207
- Isoniazid**
hepatotoxicity 5: 465, 466
- Isoprenaline**
tongue ulceration 6: 305
- K**
- Keratoconjunctivitis**
treatment 6: 272
- Keratoconjunctivitis sicca**
treatment 6: 273
- Ketamine**
mental effects 5: 241-242
- Kinins**
inflammation role in 6: 107
- L**
- Laboratory test values**
pentazocine 5: 84
streptokinase 5: 432
- Labour**
analgesics, strong 5: 134, 137
- Lactulose**
constipation 5: 225

- Lanatoside C
pharmacokinetics 6: 202-204
- Laxatives
clinical use 5: 224-226
colonic disease 6: 61
mode action 5: 224-226
toxicity 5: 226
types 5: 224
- Leukaemia
CNS prophylaxis 6: 316
septicaemia prophylaxis 6: 455
- Leukaemia, acute granulocytic
treatment in adults 5: 347
- Leukaemia, acute myelogenous
management, adults 6: 295
- Levallorphan
premedicant
compared with
pentazocine 5: 32
- Levodopa
adrenergic receptor blocking agents 6: 375
adverse effects and interactions to minimise 6:
382-383
cardiovascular 6: 382
gastro-intestinal 6: 382
psychiatric 6: 383
amantadine interactions 6: 373
amphetamine interactions 6: 374
anticholinergic drug interactions 6: 372
antidepressants, tricyclic interactions 6: 374
apomorphine interactions 6: 374
butyrophenone interactions 6: 375
catecholamine metabolising enzyme interactions 6:
368
catechol-O-methyl-transferase inhibitor interactions 6:
372
chemical interactions 6: 366
cholinergic drug interactions 6: 372
dopa decarboxylase inhibitor interactions 6: 369
dopamine β -hydroxylase inhibitor interactions 6: 370
fatty acids, free interaction 6: 381
gastro-intestinal absorption interactions 6: 367-368
gonadotrophin interactions 6: 380
growth hormone interactions 6: 381
guanethidine interactions 6: 376
hydroxytryptophan interactions 6: 378
insulin release 6: 381
manganese interactions 6: 385
melatonin interactions 6: 379
L-methionine interactions 6: 384
 α -methyl-p-tyrosine interactions 6: 371
3-O-methyldopa interactions 6: 384
mitotic interactions 6: 376
monoamine oxidase inhibitor interactions 6: 371
morphine interactions 6: 385
mydriatic interactions 6: 376
phenothiazine interactions 6: 375
phenylbutazone interactions 6: 384
physical interactions 6: 366
probenecid interactions 6: 378
prolonged therapy 6: 299
pyridoxine interactions 6: 370
renin activity interaction 6: 381
reserpine interactions 6: 375
tetraabenazine interactions 6: 375
thioxanthene interactions 6: 385
tryptophan interactions 6: 377
- Levorphanol
analgesic activity 5: 122
duration intramuscular dose 5: 117
oral efficacy 5: 117
postoperative pain 5: 136
premedicant
compared with
pentazocine 5: 32
- Lichen planus, mucosal
diagnosis 5: 457-458
treatment 5: 460-461
- Lichen planus, oral
vitamin A acid 6: 289
- Lidocaine
see lignocaine
- Lignocaine
cardiac arrhythmias
clinical application 5: 280, 298, 299
dosage 5: 294
modes of action 5: 278-280
pharmacokinetics 5: 280
toxicity 5: 280
digitalis toxicity 6: 192
- Lipid lowering drugs
hypolipidaemic drugs qv
- Lipids, blood
hyperlipidaemia qv
metabolism 6: 15-18
transport 6: 15-18
- Lipoproteins, plasma
classification 6: 15
hyperlipoproteinaemia qv
hypolipidaemic drugs 6: 26
lipid composition 6: 16
metabolism 6: 17
protein composition 6: 16
- Liquorice
hypertension 6: 353
- Lumbar disc disease
corticosteroids 6: 437
- Lupus erythematosus, systemic
azathioprine 6: 293
chlorthalidoxepoxide 6: 150
- Lysosomes
inflammation: role in 6: 109
- M
- Mandrax
misuse 6: 167-168
- Manganese
levodopa interactions 6: 385
- Marihuana
dose-response in man 5: 154
effects in man 5: 154, 155
environmental influences 5: 155
- Measles
pathogenesis 6: 315
vaccine failure 6: 302

- Meclofenamic acid
 prostaglandin synthesis 6: 113
 Mefenamic acid
 prostaglandin synthesis 6: 113
 Melanocyte stimulating hormone
 levodopa interactions 6: 379
 Melatonin
 levodopa interactions 6: 379
 Meningitis
 diagnosis 6: 446
 treatment 6: 446
 Menopause
 disorders
 treatment 6: 137-142
 Meperidine
 see pethidine
 Methadone
 analgesic activity 5: 123
 duration intramuscular dose 5: 117
 oral efficacy 5: 117
 pain, cardiac
 compared with
 pentazocine 5: 41-42
 pharmacological effects 5: 123
 Methaqualone
 misuse 6: 167-168, 313
 L-Methionine
 levodopa interactions 6: 384
 Methotrexate
 liver abnormalities 6: 148
 pneumonitis 6: 60
 psoriasis 6: 286
 Methoxyflurane
 renal transplants and renal damage 6: 76
 Methylidopa
 compared with
 clonidine 5: 340
 3-O-Methylidopa
 levodopa interactions 6: 384
 α -Methyl-p-tyrosine
 levodopa interactions 6: 371
 Metoclopramide
 oesophagitis, reflux 5: 451
 Metronidazole
 Vincent's infection 5: 460
 Migraine
 diagnosis 5: 216
 treatment 5: 216-217
 Minocycline
 gonorrhoea 5: 151
 Mitotics
 levodopa interactions 6: 376
 Monoamine oxidase inhibitors
 drug interactions 5: 171, 184, 198
 hypertension 6: 353-354
 interaction with
 analgesics, strong 5: 128
 levodopa 6: 371
 sympathomimetic amines 6: 353
 Monoamines, brain
 pentazocine effect on 5: 47-48
 Morphine
 anaesthesia 6: 305-309
 analgesic activity
 compared with
 pentazocine 5: 51-52
 cancer, gynaecological 5: 30
 duration intramuscular dose 5: 117
 levodopa interactions 6: 385
 myocardial infarction 5: 135, 137
 oral efficacy 5: 117
 pain, cardiac
 compared with
 pentazocine 5: 41-42
 pain, postoperative
 compared with
 pentazocine 5: 15-26
 pharmacokinetics 5: 126-128
 pharmacological effects 5: 116-121
 premedicant
 compared with
 pentazocine 5: 32-34
 pre-operative mediant
 paediatrics
 compared with
 pentazocine 5: 33
 respiratory depression induction
 compared with
 pentazocine 5: 53
 Morphine sulphate
 see morphine
 Muscle relaxant activity
 pentazocine 5: 48
 Muscle relaxants, skeletal
 drug interactions 5: 208-209
 Mydriatics
 drug interactions 5: 209
 levodopa interactions 6: 376
 Myocardial infarction
 anaesthesia, general 5: 333
 analgesics, strong 5: 135, 137
 anticoagulants after 6: 291
 digitalis therapy 6: 155
 digoxin 6: 219
 management 6: 434
 pentazocine: cardiovascular effects in patients with 5:
 60-62
 streptokinase 5: 408-419
 Myositis ossificans progressiva
 diphosphonate therapy 5: 342
- N
- Nalorphine
 pharmacological effects 5: 124
 premedicant
 compared with
 pentazocine 5: 32
 Naloxone
 narcotic overdose 6: 429
 Narcotic antagonist activity
 pentazocine 5: 43-44, 52-53
 Narcotic antagonists
 nalorphine qv
 pentazocine qv
 naloxone 6: 429

- Nasal polypi
ACTH 6: 289
- Neomycin
dermatitis 5: 332
hyperlipoproteinaemia
clinical use 6: 36
side-effects 6: 36
hypolipidaemic action 6: 29
- Neonates
hexachlorophane skin care 5: 97-107
otitis media: diagnosis/management 5: 344
- Neoplastic disease
pentazocine 5: 43
- Nephrotoxicity
methoxyflurane 6: 76
- Neuralgia, migrainous
diagnosis 5: 217
treatment 5: 218
- Neuralgia, trigeminal
dental malocclusions 6: 453
management 5: 212-215
- Neuroleptanalgesia
pentazocine 5: 38
compared with
dextromoramide 5: 38
phenoperidine 5: 38
- Newborn
gentamicin dosage 6: 55-57
- Nicotinic acid
hyperlipoproteinaemia
clinical use 6: 29-31
side-effects 6: 30
hypolipidaemic action 6: 27
- Nicotinyl alcohol
hyperlipoproteinaemia
side-effects 6: 30
- Niflumic acid
prostaglandin synthesis 6: 113
- Nitrazepam
bronchitis 6: 149
- Nitrous oxide-oxygen anaesthesia
pentazocine supplementation 5: 36-37
- Norethisterone
low dose, contraceptive use 6: 169-181
efficacy 6: 178
metabolism 6: 172
mode of action 6: 171
rationale for use 6: 170
side-effects 6: 178
- Norethisterone acetate
hyperlipoproteinaemia
clinical use 6: 37
- Norgestrel
low dose, contraceptive use 6: 169-181
efficacy 6: 173
mode of action 6: 171
rationale for use 6: 170
side-effects 6: 176
- O
- Obesity
digitalis dosage 5: 306
digoxin 6: 219
- Obstetrics
pentazocine 5: 38-41
- Occlusions
arterial, thromboembolic qv
arterial, non-recent qv
retinal artery or vein qv
- Oesophageal sphincter pressure, lower
gastro-oesophageal competence 5: 447-448
- Oesophagitis
diagnosis 5: 448-449
treatment 5: 446-452
- Oestrogen
deficiency 6: 137
menopausal disorders 6: 140-142
- Oestrogens
hypertension 6: 353
hyperlipoproteinaemia
clinical use 6: 37
side-effects 6: 37
- Opiate antagonists
nalorphine qv
pentazocine qv
- Opiates
see analgesics, strong
- Oral ulceration
diagnosis 5: 454-458
drug-induced 5: 456-457
treatment 5: 458-461
- Orciprenaline
asthma
compared with
terbutaline 6: 326, 327
- Otitis externa
treatment 6: 261-266
- Otitis media
neonates: diagnosis/management 5: 344
- Ototoxicity
gentamicin 5: 227
- Oxycodone
analgesic activity 5: 122
duration intramuscular dose 5: 117
oral efficacy 5: 117
- Oxymorphone
analgesic activity 5: 121
duration intramuscular dose 5: 117
oral efficacy 5: 117
- P
- Paediatrics
pre-operative medication
pentazocine
compared with
morphine 5: 33
- Pain
analgesics, clinical evaluation 5: 130-132
analgesics, strong: clinical use 5: 133-137
acute pain 5: 133, 134-137
childbirth 5: 134, 137
myocardial infarction 5: 135, 137
postoperative 5: 136, 137
trauma 5: 136
chronic pain 5: 133
mechanisms of 5: 111-115

- stimulus 5: 111
- neurological 5: 112
- extended gate control theory 5: 112-114
- central control trigger 5: 114
- action system 5: 115
- Pain, cardiac
 - pentazocine 5: 41-42
 - compared with
 - diamorphine 5: 41-42
 - methadone 5: 41-42
 - morphine 5: 41-42
- Pain, chronic
 - pentazocine
 - oral administration 5: 30-31
 - parenteral administration 5: 27-30
- Pain, dental
 - pentazocine 5: 42
- Pain, intractable
 - hypertonic saline 6: 312
- Pain, obstetric
 - pentazocine 5: 38-41
 - compared with
 - pethidine 5: 38-41
- Pain, postoperative
 - pentazocine 5: 14-27
 - compared with
 - morphine 5: 15-26
 - pethidine 5: 15-26
 - oral administration 5: 26-27
 - parenteral administration 5: 13-26
- Papaveretum
 - duration intramuscular dose 5: 117
 - oral efficacy 5: 117
- Parabens
 - dermatitis 5: 332
- Parkinsonism
 - levodopa interactions 6: 364-388
- PAS
 - hyperlipoproteinaemia
 - clinical use 6: 36
 - hypolipidaemic action 6: 27
- Pediculosis pubis
 - diagnosis 5: 148
- Pemphigus
 - azathioprine 6: 288
- D-Penicillamine
 - rheumatoid arthritis, severe 6: 294
- Penicillin
 - gonorrhoea 5: 150
 - syphilis 5: 152
 - pivampicillin 6: 94-103
- Pentazocine
 - absorption 5: 65-67
 - adverse reactions 5: 72-77
 - compared with
 - other analgesics 5: 75-77
 - d-isomer 5: 77
 - l-isomer 5: 77
 - anaesthesia supplement 5: 34-37
 - anaesthesia, thiopentone: Effect on 5: 48-49
 - analgesic activity 5: 44-45, 51-52
 - compared with
 - morphine 5: 51-52
 - site of action 5: 45
 - anticonvulsant activity 5: 48
 - antitussive activity 5: 64
 - autonomic effects 5: 74
 - behavioural effects 5: 47
 - blood levels 5: 2-3, 65-67
 - blood pressure 5: 57-59
 - brain monoamines, effect on 5: 47-48
 - cancer, gynaecological 5: 30
 - mode of action 5: 60
 - cardiovascular effects 5: 46
 - cardiovascular effects in patients with
 - myocardial infarction 5: 60-62
 - cardiovascular haemodynamic effects 5: 57-62
 - central nervous system effects 5: 46-48, 73-74
 - childbirth 5: 134, 137
 - clinical pharmacology 5: 1-5
 - composition of dosage forms 5: 71
 - contra-indications 5: 78
 - dependence liability 5: 126
 - dermatological and local effects 5: 74-75
 - distribution 5: 2-3, 69-71
 - dosage 5: 16-21, 23
 - dosage and administration 5: 84-86
 - dosage, oral 5: 85-86
 - dosage, parenteral 5: 84-85
 - drug abuse 5: 82-83
 - drug dependence 5: 78-79, 80-84
 - drug interactions 5: 77-78
 - duration intramuscular dose 5: 117
 - dysmorphology 5: 50
 - electroencephalograph 5: 65
 - excretion 5: 3-4, 69
 - gastro-intestinal effects 5: 72-73
 - gastro-intestinal function 5: 48, 62-63
 - half-life 5: 2-3, 67
 - heart: effect on 5: 59-60
 - indications for use 5: 72
 - intracranial pressure 5: 63-64
 - laboratory test values 5: 84
 - metabolism 5: 3-4, 67-69
 - muscle relaxant activity 5: 48
 - myocardial infarction 5: 135, 137
 - narcotic antagonist activity 5: 43-44, 52-53
 - neoplastic disease 5: 43
 - neuroleptanalgesia 5: 38
 - compared with
 - dextromoramide 5: 38
 - phenoperidine 5: 38
 - nitrous oxide-oxygen anaesthesia supplement 5: 36-37
 - obstetrics 5: 38-41
 - ophthalmic effects 5: 74
 - oral efficacy 5: 117
 - overdosage 5: 86
 - overdosage: naloxone treatment 6: 429
 - pain after dental extraction 5: 42
 - pain, cardiac 5: 41-42
 - compared with
 - diamorphine 5: 41-42
 - methadone 5: 41-42
 - morphine 5: 41-42
 - pain, chronic

- oral administration 5: 30–31
- parenteral administration 5: 27–30
- pain, obstetrics
 - compared with
 - pethidine 5: 38–41
- pain, postoperative 5: 13–27
 - compared with
 - morphine 5: 15–26
 - oral administration 5: 26–27
 - parenteral administration 5: 13–26
- pharmacodynamic studies 5: 43–65
- pharmacokinetic studies 5: 65–71
- pharmacological effects 5: 125–126
- placental transfer 5: 70–71
- postoperative pain 5: 136, 137
- precautions in use 5: 78–79
- pregnancy 5: 79
- premedicant
 - compared with
 - diazepam 5: 33
 - levallorphan 5: 32
 - levorphanol 5: 32
 - morphine 5: 32–34
 - nalorphine 5: 32
 - pethidine 5: 32
 - pentazocine 5: 32
- pre-operative medicant 5: 32–34
- paediatrics
 - compared with
 - morphine 5: 33
- psychiatric effects 5: 73–74
- psychotomimetic effects 5: 47
- pupillary size 5: 64
- renal function 5: 62
- reproduction studies 5: 50
- respiration: effect on 5: 45–46, 53–57
- respiration: effect on in presence of pain or associated disease 5: 56
- respiratory depression induction
 - compared with
 - morphine 5: 53
 - reversal of 5: 46, 56–57
- respiratory effects 5: 74
- sedation 5: 75
- structural formula 5: 71
- therapeutic trials 5: 13–43
- toxicology studies 5: 49–50
- urological conditions 5: 42–43
- uterine contractility 5: 63
- venomotor reflexes: effect on 5: 58–59
- Peptide, connective tissue activating
 - inflammation: role in 6: 114
- Periadenitis mucosa
 - diagnosis 5: 455
 - treatment 5: 459
- Pethidine
 - analgesic activity 5: 122
 - childbirth 5: 134, 137
 - duration intramuscular dose 5: 117
 - myocardial infarction 5: 135
 - oral efficacy 5: 117
 - pain, obstetrics
 - compared with
 - pentazocine 5: 38–41
 - pharmacological effects 5: 122
 - premedicant
 - compared with
 - pentazocine 5: 32
- Pharmacokinetics
 - drug interactions 5: 161–186
- Phenazocine
 - analgesic activity
 - duration intramuscular dose 5: 117
 - oral efficacy 5: 117
 - pre medicant
 - compared with
 - pentazocine 5: 32
- Phenoperidine
 - analgesic activity 5: 122
 - neuroleptanalgesia
 - compared with
 - pentazocine 5: 38
 - pharmacological effects 5: 122
- Phenothiazines
 - interaction with
 - levodopa 6: 375
 - antihypertensive drugs 6: 354
 - withdrawal
 - extrapyramidal disorders 5: 232
 - psychiatric relapse 5: 232
- Phenylbutazone
 - anti-inflammatory action 6: 104–116
 - levodopa interactions 6: 384
 - prostaglandin synthesis 6: 113
- Phenytoin
 - cardiac arrhythmias
 - clinical application 5: 281, 299, 301
 - dosage 5: 294
 - modes of action 5: 280–281
 - pharmacokinetics 5: 282
 - toxicity 5: 282–283
 - digitalis toxicity 6: 193
 - single daily dosage 5: 462–463
- Phosphorylation, oxidative
 - uncoupling
 - inflammation: role in 6: 110
- Photodermatoses
 - causes 6: 255–257
 - diagnosis 6: 258–259
 - treatment 6: 259–260
- Pinguecula
 - treatment 6: 273–274
- Pivampicillin
 - absorption 6: 95
 - antibacterial activity 6: 95
 - distribution 6: 97
 - excretion 6: 97
 - gonorrhoea 6: 99
 - pharmacokinetics 6: 95–98
 - respiratory infections 6: 99
 - side-effects 6: 100
 - urinary infections 6: 98
- Placental transfer
 - analgesics, strong 5: 127
 - pentazocine 5: 70–71
- Plasminogen

- activation by streptokinase 5: 371-374
- inhibition of streptokinase-induced activation 5: 375
- Pneumonia**
 - Haemophilus influenzae* in adults 6: 68
- Pneumonitis**
 - methotrexate 6: 60
- Polyps, nasal**
 - management 6: 449
- Potassium**
 - cardiac arrhythmias
 - clinical application 5: 288
 - dosage 5: 294
 - modes of action 5: 288
 - digitalis toxicity 5: 306-308; 6: 191-192
- Potassium supplements**
 - 5: 210
 - clinical use 6: 222-229
 - diuretic therapy 6: 225-229
- Potassium, total body**
 - diuretic therapy 6: 146
- Pregnancy**
 - anaemia 6: 251
 - anaesthetic practice 5: 335
 - antihypertensive drugs 6: 358
 - bacteriuria 6: 456
 - pentazocine 5: 79
 - rubella vaccination 6: 301
 - streptokinase 5: 406-408
 - thyrotoxicosis: treatment of 6: 442
- Premedication**
 - pentazocine
 - compared with
 - diazepam 5: 33
 - levallorphan 5: 32
 - levorphanol 5: 32
 - morphine 5: 32-34
 - nalorphine 5: 32
 - phenazocine 5: 32
 - pethidine 5: 32
- Pre-operative medication**
 - paediatrics
 - pentazocine
 - compared with
 - morphine 5: 33
- Priapism**
 - streptokinase 5: 425
- Probenecid**
 - gonorrhoea 5: 150-151
 - levodopa interactions 6: 378
- Procainamide**
 - clinical application 5: 278, 295, 296, 297, 298, 299
 - digitalis toxicity 6: 193
 - dosage 5: 294
 - modes of antiarrhythmic action 5: 277-278
 - pharmacokinetics 5: 278
 - toxicity 5: 278
- Procaine penicillin**
 - gonorrhoea 5: 150
 - syphilis 5: 152
- Prostaglandins**
 - hypertension 5: 341
- Prostaglandins**
 - inflammation: role in 6: 111-114
- Protein binding**
 - anti-inflammatory drugs, acidic 6: 113, 115
 - drug interactions 5: 174
- Psoriasis**
 - liver abnormalities 6: 148
 - methotrexate/hydroxyurea 6: 286
 - staphylococcal infection 6: 287
- Psychotomimetic effects**
 - pentazocine 5: 47
- Pulmonary disease**
 - digitalis toxicity 5: 305
- Pulmonary embolism, acute**
 - streptokinase 5: 381-387
 - compared with heparin 5: 383-387
- Pulmonary oedema, acute**
 - treatment 5: 325-326
- Pupillary size**
 - pentazocine effect 5: 64
- Purgatives**
 - colon toxicity 5: 226
- Pyelonephritis**
 - diagnosis 6: 417-424
 - treatment 6: 424-426
- Pyridoxine**
 - levodopa interactions 6: 370
- Q**
- Quinidine**
 - clinical application 5: 276, 295, 296, 297, 300
 - dosage 5: 294
 - modes of antiarrhythmic action 5: 274-276
 - pharmacokinetics 5: 276-277
 - toxicity 5: 277
 - digitalis toxicity 6: 193
- R**
- Radiotherapy**
 - tumour swelling: prevention 6: 72
- Receptors, drug**
 - drug interactions 5: 175
- Red cell concentrates**
 - rationale for use 6: 127-136
- Renal artery thromboembolism**
 - streptokinase 5: 424-425

- Renal excretion
 - drug interactions 5: 180-182
 - mechanisms of drug elimination 5: 250-252
- Renal failure
 - anaemia 6: 249
 - anaesthesia 5: 248-249
 - co-trimoxazole 6: 430
 - digoxin 6: 213-216
 - digoxin 6: 213-216
- Renal function
 - digoxin dosage 5: 306
 - pentazocine effect 5: 62
- Renal physiology
 - anaesthesia and surgery 5: 246-247
 - regulatory functions 5: 246-247
- Renin activity
 - levodopa 6: 381
- Reserpine
 - levodopa interactions 6: 375
- Respiration
 - pentazocine effect 5: 45-46, 53-57
- Respiratory depression, drug-induced
 - morphine 5: 53
 - pentazocine 5: 53
 - compared with
 - morphine 5: 53
 - reversal of 5: 46, 56-57; 6: 429
- Respiratory disease, lower
 - epidemiology in children 6: 281-284
- Retinal occlusion
 - streptokinase 5: 422-423
- R-factors
 - trimethoprim resistance 5: 240
- Rheumatic fever
 - prophylactic therapy in patients with uncertain history
 - 5: 245
- Rheumatoid arthritis
 - gold therapy 5: 244-245
 - D-penicillamine 6: 294
 - treatment 6: 153
- Rhinitis, allergic
 - cromoglycate, sodium 6: 447
- Rifampicin
 - CSF concentrations 6: 145
 - hepatotoxicity 5: 466
 - intermittent, adverse reactions 5: 230
- Rubella vaccine
 - arthritic reaction 6: 433
 - current status 6: 300-301
 - failure 6: 303, 304
 - pregnant women, adverse effects 6: 301
- S
- Salbutamol
 - asthma
 - compared with
 - terbutaline 6: 326, 327
- Salicylates
 - anti-inflammatory action 6: 104-116
 - intoxication 6: 454
- Salmonellosis
 - cause 6: 407
 - treatment 6: 411
- Serotonin
 - inflammation: role in 6: 106
- Sexually transmitted disease
 - diagnosis 5: 148
 - incidence 5: 145
- Shigellosis
 - cause 6: 407
 - treatment 6: 411
- Side-effects
 - see drug reactions, adverse
- Sinus syndrome, sick
 - treatment 6: 436
- Sinusitis, maxillary
 - bromhexine 6: 448
- β -Sitosterol
 - hyperlipoproteinaemia
 - clinical use 6: 35
 - hypolipidaemic action 6: 29
- Skin care
 - neonates, hexachlorophane 5: 97-107
- Sodium cromoglycate
 - see cromoglycate, sodium
- Sosogon
 - see pentazocine
- Spectinomycin
 - gonorrhoea 5: 151
- Spiramycin
 - gonorrhoea 5: 152
- Spiroinolactone
 - heart failure, refractory 5: 325, 328
 - potassium repletion
 - clinical use 6: 226-229
- Streptokinase 5: 357-445
 - administration
 - control of therapy 5: 436-437
 - post-infusion anticoagulants 5: 437
 - allergic reactions 5: 429-430
 - angina pectoris 5: 427
 - anticoagulants to prevent re-thrombosis 5: 380, 437
 - antigenicity 5: 371
 - arterial occlusions, non-recent 5: 418-422
 - bleeding 5: 428-429
 - blood viscosity 5: 376-377
 - clinical pharmacology 5: 364-381
 - coagulation defect 5: 377-378
 - coagulation, disseminated intravascular 5: 425-426
 - complications 5: 428-432
 - development 5: 370-371
 - dosage 5: 355, 378-380, 434-437
 - initial 5: 435
 - corticosteroid use 5: 435
 - maintenance 5: 436
 - children 5: 436
 - drug interactions 5: 432
 - erythrocyte aggregation, inhibition 5: 376-377
 - inhibition of action 5: 375-376
 - laboratory test values 5: 432
 - mechanism of action 5: 371-377
 - myocardial infarction, acute 5: 408-419
 - obstetric use 5: 406-408
 - plasminogen activation 5: 371-374
 - precautions in use 5: 432-434
 - priapism 5: 425

- pulmonary embolism, acute 5: 381-387
 renal artery thromboembolism 5: 424-425
 re-thrombosis 5: 431
 retinal occlusion 5: 422-423
 shunts, arteriovenous occluded 5: 427
 side-effects 5: 428-430, 432
 storage and stability 5: 438
 therapeutic uses 5: 356, 381-427
 thromboembolic arterial occlusions 5: 398-406
 comparison with surgery 5: 405
 thromboembolic complications 5: 430-431
 thromboembolism, acute cerebral 5: 423-424
 thrombosis, deep vein 5: 388-398
 post-phlebotic sequelae 5: 396-398
- Sulphur
 acne vulgaris 5: 337
- Sympathomimetic amines
 asthma 6: 121-122
 interaction with antihypertensive drugs 6: 354
- Syphilis
 diagnosis 5: 147
 incidence 5: 144
 treatment
 penicillin 5: 152
 tetracyclines 5: 152
 erythromycin estolate 5: 152
- Systoles, atrial premature
 treatment 5: 295
- T
- Tachycardia, atrial
 treatment 5: 296
- Talwin
 see pentazocine
- Teeth
 tetracyclines 6: 321-323, 432
- Terbutaline
 asthma 6: 324-332
 clinical use 6: 326-329
 compared with
 adrenaline 6: 327
 ephedrine 6: 327
 orciprenaline 6: 326, 327
 proxiphylline 6: 327
 salbutamol 6: 326, 327
 dosage 6: 330
 pharmacology 6: 325
 side-effects 6: 329
- Tetrabenazine
 levodopa interactions 6: 375
- Tetracyclines
 gonorrhoea 5: 151
 oral ulceration treatment 5: 458, 459
 syphilis 5: 152
 tooth staining 6: 321-323, 432
 urethritis, nonspecific 5: 153
- Tetrahydrocannabinol
 dose response in man 5: 154
 effect in man 5: 154
- Thiamphenicol
 gonorrhoea 5: 151
- Thiopentone
 pentazocine effect on 5: 48-49
- Thioxanthenes
 levodopa interactions 6: 385
- Thromboembolic arterial occlusions
 streptokinase 5: 398-406
- Thromboembolism, acute cerebral
 streptokinase 5: 423-424
- Thromboembolism, renal artery
 streptokinase 5: 424-425
- Thrombolytic agents
 aim of therapy 5: 369-370
 classification 5: 353, 369
 mechanism of action 5: 353
 status 5: 353-356
 streptokinase qv
 urokinase qv
- Thrombosis
 prevention 3: 353-356
 treatment 3: 353-356
- Thrombosis, deep vein
 streptokinase 5: 388-398
- Thrombus
 dissolution by streptokinase 5: 374-375
- Thyroid disease
 digoxin 6: 216-218
- Thyroid drugs
 drug interactions 5: 210
- Thyroid hormone
 antidepressants, tricyclic: potentiation of 5: 235, 236
- Thyrototoxicosis
 pregnancy: treatment of 6: 442
 radio-iodine treatment 6: 441
- d-Thyroxine
 cardiotoxicity 6: 37
 hyperlipoproteinaemia
 clinical use 6: 36
 side-effects 6: 37
 hypolipidaemic drugs 6: 29
- TMJ pain-dysfunction syndrome
 management 6: 296
- Tongue
 isoprenaline ulceration 6: 305
- Trachoma
 treatment 6: 271-272
- Tranexamic acid
 inhibition action streptokinase 5: 375, 408
- Tranquillisers
 drug interactions 5: 210-211
- Triamterene
 heart failure, refractory 5: 325, 328
 potassium repletion
 clinical use 6: 226-229
- Triglyceride
 'normal limits' 6: 22
- Trimethoprim
 see also co-trimoxazole
 resistance and R-factors 5: 240
 resistant coliforms 5: 239
- Trimethoprim-sulphamethoxazole
 gonorrhoea 5: 152
- Tryptophan
 imipramine, compared with 5: 235
 levodopa interactions 6: 377

- Tuberculosis, meningeal
rifampicin CSF concentrations 6: 145
- U
- Ulceration, aphthous
diagnosis 5: 454
treatment 5: 458-459
- Urea
eczema, atopic
+ hydrocortisone 6: 439
- Urethritis, nonspecific
diagnosis 5: 148
incidence 5: 144
treatment 5: 153
tetracyclines 5: 153
erythromycin 5: 153
- Urinary casts
diuretics 5: 230
- Urinary infection
ampicillin, cephalexin, co-trimoxazole compared 5:
472
children
management 6: 230-236
pivampicillin 6: 98
pregnancy 6: 456
- Urokinase
properties 5: 354
pulmonary embolism 5: 387
- Urological conditions
pentazocine 5: 42-43
- Uterine contractility
pentazocine 5: 63
- V
- Varicella-zoster
cytarabine 6: 444
- Vasopressor agents
drug interactions 5: 211
- Venereal disease
diagnosis 5: 145-149
incidence 5: 144
treatment 5: 149-153
- Ventricular tachyarrhythmias
treatment 5: 298-300
- Verapamil
cardiac arrhythmias
mode of action 5: 258
therapeutic use 5: 259
- Vincent's infection
diagnosis 5: 456
treatment 5: 460
- Vitamin A acid
lichen planus, oral 6: 289
- W
- Warts, genital
diagnosis 5: 149
- Win 20,228
see pentazocine
- X
- Xanthines
asthma 6: 122-123
- Xerostomic reactions
drug-induced 5: 229
- Y
- Yersinia enterocolitica
outbreak 6: 292
- Z
- Zinc
cutaneous healing 6: 161

